{"resourceType":"Bundle","id":"mii-exa-befund-bundle-befund-fgfr2-fusion","type":"transaction","timestamp":"2022-12-16T13:47:00+01:00","entry":[{"fullUrl":"https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-patient-fgfr2-fusion","resource":{"resourceType":"Patient","id":"mii-exa-molgen-patient-fgfr2-fusion","identifier":[{"use":"usual","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v3-ObservationValue","code":"PSEUDED"}]},"system":"https://www.charite.de/fhir/sid/pseudonym","value":"3337167192"}],"gender":"female","birthDate":"1964-05","deceasedBoolean":false,"address":[{"type":"both","postalCode":"10","country":"DE"}]},"request":{"method":"PUT","url":"Patient/mii-exa-molgen-patient-fgfr2-fusion"}},{"fullUrl":"https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-practitioner-lab","resource":{"resourceType":"Practitioner","id":"mii-exa-molgen-practitioner-lab","active":true,"name":[{"use":"official","text":"Dr. Daniel Schmidt","family":"Schmidt","given":["Daniel"],"prefix":["Dr."]}]},"request":{"method":"PUT","url":"Practitioner/mii-exa-molgen-practitioner-lab"}},{"fullUrl":"https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-practitioner-physician","resource":{"resourceType":"Practitioner","id":"mii-exa-molgen-practitioner-physician","active":true,"name":[{"use":"official","text":"Dr. Linda Rubens","family":"Rubens","given":["Linda"],"prefix":["Dr."]}]},"request":{"method":"PUT","url":"Practitioner/mii-exa-molgen-practitioner-physician"}},{"fullUrl":"https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-molekulargenetischer-befundbericht-fgfr2-fusion","resource":{"resourceType":"DiagnosticReport","id":"mii-exa-molgen-molekulargenetischer-befundbericht-fgfr2-fusion","meta":{"profile":["https://www.medizininformatik-initiative.de/fhir/ext/modul-molgen/StructureDefinition/molekulargenetischer-befundbericht","http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/genomics-report"]},"extension":[{"url":"http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/recommended-action","valueReference":{"reference":"Task/mii-exa-molgen-medikationsempfehlung-fgfr2-fusion"}}],"basedOn":[{"reference":"ServiceRequest/mii-exa-molgen-anforderung-fgfr2-fusion"}],"status":"final","category":[{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0074","code":"GE","display":"Genetics"}]}],"code":{"coding":[{"system":"http://loinc.org","code":"51969-4","display":"Genetic analysis report"}]},"subject":{"reference":"Patient/mii-exa-molgen-patient-fgfr2-fusion"},"performer":[{"reference":"Practitioner/mii-exa-molgen-practitioner-lab"}],"result":[{"reference":"Observation/mii-exa-molgen-diagnostische-implikation-fgfr2-fusion"},{"reference":"Observation/mii-exa-molgen-variante-fgfr2-fusion"},{"reference":"Observation/mii-exa-molgen-therapeutische-implikation-fgfr2-fusion"}],"conclusion":"Nachweis FGFR2-Fusion. Empfehlung: Hochselektive FGFR-Inhibitor-Therapie."},"request":{"method":"PUT","url":"DiagnosticReport/mii-exa-molgen-molekulargenetischer-befundbericht-fgfr2-fusion"}},{"fullUrl":"https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-anforderung-fgfr2-fusion","resource":{"resourceType":"ServiceRequest","id":"mii-exa-molgen-anforderung-fgfr2-fusion","meta":{"profile":["https://www.medizininformatik-initiative.de/fhir/ext/modul-molgen/StructureDefinition/anforderung-genetischer-test"]},"identifier":[{"system":"https://www.charite.de/fhir/auftragsnummern","value":"PRK4QE59A"}],"status":"active","intent":"order","category":[{"coding":[{"system":"http://snomed.info/sct","code":"108252007","display":"Laboratory procedure (procedure)"}]}],"code":{"coding":[{"system":"http://snomed.info/sct","code":"405825005","display":"Molecular genetic test (procedure)"}],"text":"Therapierelevante genetische Veränderungen bei Intrahepatischem Gallengangskarzinom"},"subject":{"reference":"Patient/mii-exa-molgen-patient-fgfr2-fusion"},"authoredOn":"2022-11-30","requester":{"reference":"Practitioner/mii-exa-molgen-practitioner-physician"},"reasonCode":[{"coding":[{"system":"http://snomed.info/sct","code":"109842005","display":"Intrahepatic bile duct carcinoma (disorder)"},{"system":"http://fhir.de/CodeSystem/bfarm/icd-10-gm","version":"2022","code":"C22.1","display":"Intrahepatisches Gallengangskarzinom"}]}]},"request":{"method":"PUT","url":"ServiceRequest/mii-exa-molgen-anforderung-fgfr2-fusion"}},{"fullUrl":"https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-variante-fgfr2-fusion","resource":{"resourceType":"Observation","id":"mii-exa-molgen-variante-fgfr2-fusion","meta":{"profile":["https://www.medizininformatik-initiative.de/fhir/ext/modul-molgen/StructureDefinition/variante","http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/variant"]},"basedOn":[{"reference":"ServiceRequest/mii-exa-molgen-anforderung-fgfr2-fusion"}],"status":"final","category":[{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/observation-category","code":"laboratory","display":"Laboratory"}]}],"code":{"coding":[{"system":"http://loinc.org","code":"69548-6","display":"Genetic variant assessment"}]},"subject":{"reference":"Patient/mii-exa-molgen-patient-fgfr2-fusion"},"valueCodeableConcept":{"coding":[{"system":"http://loinc.org","code":"LA9633-4","display":"Present"}]},"method":{"coding":[{"system":"http://loinc.org","code":"LA26398-0","display":"Sequencing"},{"system":"http://loinc.org","code":"86206-0","display":"Whole genome sequence analysis in Blood or Tissue by Molecular genetics method"}]},"component":[{"code":{"coding":[{"system":"http://loinc.org","code":"48018-6"}]},"valueCodeableConcept":{"coding":[{"system":"http://www.genenames.org/geneId","code":"HGNC:3689","display":"FGFR2"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"48019-4"}]},"valueCodeableConcept":{"coding":[{"system":"http://sequenceontology.org","code":"SO:0001565","display":"gene_fusion"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"95123-6"}]},"valueCodeableConcept":{"coding":[{"system":"http://www.genenames.org/geneId","code":"HGNC:3689::HGNC:2697","display":"FGFR2::DBP"}]}}]},"request":{"method":"PUT","url":"Observation/mii-exa-molgen-variante-fgfr2-fusion"}},{"fullUrl":"https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-diagnostische-implikation-fgfr2-fusion","resource":{"resourceType":"Observation","id":"mii-exa-molgen-diagnostische-implikation-fgfr2-fusion","meta":{"profile":["https://www.medizininformatik-initiative.de/fhir/ext/modul-molgen/StructureDefinition/diagnostische-implikation","http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/diagnostic-implication"]},"status":"final","category":[{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/observation-category","code":"laboratory","display":"Laboratory"}]}],"code":{"coding":[{"system":"http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs","code":"diagnostic-implication","display":"Diagnostische Implikation"}]},"subject":{"reference":"Patient/mii-exa-molgen-patient-fgfr2-fusion"},"performer":[{"reference":"Practitioner/mii-exa-molgen-practitioner-lab"}],"derivedFrom":[{"reference":"Observation/mii-exa-molgen-variante-fgfr2-fusion"}],"component":[{"code":{"coding":[{"system":"http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs","code":"conclusion-string"}]},"valueString":"starke Überexpression (25-fach)"}]},"request":{"method":"PUT","url":"Observation/mii-exa-molgen-diagnostische-implikation-fgfr2-fusion"}},{"fullUrl":"https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-therapeutische-implikation-fgfr2-fusion","resource":{"resourceType":"Observation","id":"mii-exa-molgen-therapeutische-implikation-fgfr2-fusion","meta":{"profile":["https://www.medizininformatik-initiative.de/fhir/ext/modul-molgen/StructureDefinition/therapeutische-implikation","http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/therapeutic-implication"]},"status":"final","category":[{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/observation-category","code":"laboratory","display":"Laboratory"}]}],"code":{"coding":[{"system":"http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs","code":"therapeutic-implication","display":"Therapeutische Implikation"}]},"subject":{"reference":"Patient/mii-exa-molgen-patient-fgfr2-fusion"},"performer":[{"reference":"Practitioner/mii-exa-molgen-practitioner-lab"}],"derivedFrom":[{"reference":"Observation/mii-exa-molgen-variante-fgfr2-fusion"}],"component":[{"code":{"coding":[{"system":"http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs","code":"conclusion-string"}]},"valueString":"Hochselektiver FGFR2-Inhibitor RLY-4008 bei Patienten mit Cholangiokarzinomen und anderen soliden Tumoren, mit oder ohne FGFR- gerichtete Vortherapie."},{"code":{"coding":[{"system":"http://loinc.org","code":"51963-7","display":"Medication assessed [ID]"}]},"valueCodeableConcept":{"coding":[{"system":"http://www.whocc.no/atc","version":"2022","code":"L01EN","display":"Fibroblasten-Wachstumsfaktor-Rezeptor (FGFR)-Tyrosinkinase-Inhibitoren"},{"system":"http://snomed.info/sct","code":"1162485005","display":"Substance with fibroblast growth factor receptor inhibitor mechanism of action (substance)"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"93044-6"}]},"valueCodeableConcept":{"text":"m1c"}},{"code":{"coding":[{"system":"http://loinc.org","code":"81259-4"}]},"valueCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"109842005","display":"Intrahepatic bile duct carcinoma (disorder)"},{"system":"http://fhir.de/CodeSystem/bfarm/icd-10-gm","version":"2022","code":"C22.1","display":"Intrahepatisches Gallengangskarzinom"}]}}]},"request":{"method":"PUT","url":"Observation/mii-exa-molgen-therapeutische-implikation-fgfr2-fusion"}},{"fullUrl":"https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-medikationsempfehlung-fgfr2-fusion","resource":{"resourceType":"Task","id":"mii-exa-molgen-medikationsempfehlung-fgfr2-fusion","meta":{"profile":["https://www.medizininformatik-initiative.de/fhir/ext/modul-molgen/StructureDefinition/medikationsempfehlung","http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/medication-recommendation"]},"basedOn":[{"reference":"ServiceRequest/mii-exa-molgen-anforderung-fgfr2-fusion"}],"status":"requested","intent":"proposal","code":{"coding":[{"system":"http://loinc.org","code":"LA26421-0","display":"Consider alternative medication"}],"text":"Hochselektive FGFR-Inhibitor-Therapie"},"for":{"reference":"Patient/mii-exa-molgen-patient-fgfr2-fusion"},"reasonReference":{"reference":"Observation/mii-exa-molgen-therapeutische-implikation-fgfr2-fusion"}},"request":{"method":"PUT","url":"Task/mii-exa-molgen-medikationsempfehlung-fgfr2-fusion"}}]}